BenevolentAI, founded in 2013, creates and applies AI technologies to transform the way medicines are discovered and developed. BenevolentAI seeks to improve patient's lives by applying technology designed to generate better data decision making and in doing so lower drug development costs, decrease failure rates and increase the speed at which medicines are generated. The company has developed the Benevolent Platform - a discovery platform used by BenevolentAI scientists to find new ways to treat disease and personalise drugs to patients. BenevolentAI is HQ'd in London with a research facility in Cambridge (UK) and further offices in New York and Antwerp. BenevolentAI has active R&D drug programmes from discovery to PhaseIIb in disease areas such as ALS, Parkinson's, Ulcerative Colitis and Sarcopenia.
Jun-7-2019, 08:08:57 GMT